Theorem Clinical Research

Novartis

Novartis to open Center for Advanced Cellular Therapeutics at University of Pennsylvania

Monday, September 15, 2014 12:29 PM

The University of Pennsylvania’s alliance with Novartis has unveiled plans for the construction of a first-of-its-kind Center for Advanced Cellular Therapeutics (CACT) on the Penn Medicine campus in Philadelphia.

More... »


Bay Area BioEconomy Initiative appoints Pablo Cagnoni to steering committee

Friday, September 12, 2014 01:01 PM

The Bay Area BioEconomy Initiative (BAB) has named Pablo J. Cagnoni, M.D., president of Onyx Pharmaceuticals, to its steering committee. Onyx, an Amgen subsidiary, is engaged in the development and commercialization of innovative therapies to improve the lives of people with cancer.

More... »


Mallinckrodt appoints new leaders following completion of Questcor acquisition

Thursday, August 28, 2014 02:07 PM

Mallinckrodt, an Ireland-based global specialty pharmaceutical company, has announced that Gary Phillips, M.D., current senior vice president and chief strategy officer, has been appointed senior vice president and president of the company’s autoimmune and rare disease business, which includes the commercial organization supporting H.P. Acthar Gel.

More... »

Novartis provides drug candidate compounds to TB Alliance

Thursday, August 21, 2014 01:48 PM

Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development (TB Alliance), which has locations in the U.S., Brussels and South Africa, for compounds to fight tuberculosis (TB) that have been discovered at the Novartis Institutes for Tropical Diseases (NITD).

More... »

Pfizer, Gamida Cell ink investment and option agreement

Wednesday, August 20, 2014 01:31 PM

Gamida Cell, an Israel-based provider of stem cell expansion technologies and therapeutic products, has signed an investment and option agreement with Novartis Pharma. Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable for a limited period of time following achievement of certain milestones connected to the development of NiCord, anticipated to be met during 2015.

More... »

Group of 19 institutional investors seeks support for biosimilars from top biopharma companies

Thursday, August 14, 2014 02:34 PM

Don’t bad mouth biosimilars—they are needed to help hold down skyrocketing drug costs.

More... »

Pfizer, Roche join ADDPLAN DF Consortium

Monday, August 4, 2014 02:12 PM

Pfizer and Roche have joined the ADDPLAN DF Consortium. The consortium was founded in 2013 by Novartis, Janssen PharmaceuticalsEli Lilly and Aptiv Solutions, an Icon company, to lead the design and implementation of adaptive trials. The goal of the ADDPLAN DF Consortium is to develop methodologies and execution technologies that improve dose-selection, which remains a major barrier to resolving high failure rates in phase III trials.

More... »

ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

Banner Alzheimer's Institute, Novartis partner

Wednesday, July 16, 2014 01:21 PM

Researchers from the Banner Alzheimer's Institute (BAI) have partnered with Novartis in a pioneering medical trial to determine whether two investigational anti-amyloid drugs—an active immunotherapy and an oral medication—can prevent or delay the emergence of symptoms of Alzheimer's in people at particularly high risk for developing the disease at older ages.

More... »

Covance adds two to clinical development services leadership team

Monday, July 14, 2014 01:04 PM

Covance has announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as vice president and global therapeutic area head, oncology, and Rogelio Mosqueda-Garcia, M.D., Ph.D., as global vice president, early clinical services within medical and scientific affairs. Both are based in Princeton, N.J.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 22

Roche/Genentech plans pilot trial to measure patientpreference for participating at home v. at study site

Bipartisan 21st Century Cures initiative prepares to draft legislation to accelerate biomedical R&D, lower cost

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs